Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
Koichi GotoYasushi GotoToshio KuboKiichiro NinomiyaSang-We KimDavid PlanchardMyung-Ju AhnEgbert F SmitAdrianus Johannes de LangenMaurice PérolElvire Pons-TostivintSilvia NovelloHidetoshi HayashiJunichi ShimizuDong Wan KimChih-Hsi KuoJames Chih-Hsin YangKaline PereiraFu-Chih ChengAyumi TaguchiYingkai ChengWenqin FengZenta TsuchihashiPasi A JannePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
T-DXd demonstrated clinically meaningful responses at both doses. Safety profile was acceptable and generally manageable, favoring T-DXd 5.4 mg/kg.